An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.

CONCLUSION: Docetaxel, gemcitabine, and bevacizumab at this dose and schedule resulted in excessive toxicity. Despite promising efficacy, in light of efficacious and safe alternative therapies, this regimen should not be used to treat advanced NSCLC. PMID: 30602615 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30602615?dopt=Abstract

Source: The Oncologist - January 2, 2019 Category: Cancer & Oncology Authors: Patil PD, Shapiro M, Hashemi Sadraei N, Pennell NA Tags: Oncologist Source Type: research